deltatrials
Unknown PHASE3 NCT00944268

Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety

Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety

Sponsor: Ativus Farmaceutica Ltda

Conditions Anxiety Efficacy Tolerability
Interventions Passiflora, Crataegus e Salix
Updated 5 times since 2017 Last updated: Jul 23, 2009 Started: Sep 30, 2009 Primary completion: Dec 31, 2009 Completion: Jan 31, 2010

This PHASE3 trial investigates Anxiety and Efficacy and is currently ongoing. Ativus Farmaceutica Ltda leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE3

    First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ativus Farmaceutica Ltda
Data source: Ativus Farmaceutica Ltda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Santo André, Brazil